Comparison between Therapeutic Ultrasound and Anesthesia Injection in women with Tummy Pain caused by a pain point for more than 6 months

Not Applicable

Recruiting

• Conditions: Pelvic Pain; Women; R10.2; M01.975

• Registration Number: RBR-39czsv
• Lead Sponsor: Faculdade de Medicina de Ribeirão Preto - FMRP-USP

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women older than eighteen years and not menopausal with clinical diagnosis of abdominal myofascial syndrome with presence of only one active trigger point and pain above four point four (moderate pain) in the visual analogue scale (VAS) and without previous treatments.

Exclusion Criteria

Pregnant women with hip prosthesis, neoplasias in the abdomino-pelvic region, with severe osteoporosis, copper IUDs, abdominal varicose veins, cognitive deficits that make the questionnaires difficult to comprehend, women with anticoagulation or hemorrhagic disorders, local or systemic infections, allergy to anesthetics, acute muscle trauma, extreme fear of needles, history of complaints of chronic musculoskeletal pain such as fibromyalgia, chronic fatigue or diabetes. Also included in the exclusion criteria are those who use chronic painkillers, anti inflammatories, and tricyclic antidepressants who have used aspirin within three days prior to injection, all patients with suspected interstitial cystitis, bowel syndrome irritable or other disease that justifies or contributes to CPP, will also be part of the criteria for exclusion of endometrioma or hernia evidenced by ultrasound of the abdominal wall, abdominal wall infections and women who are missing after the start of treatment.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expected outcome 1 - clinical pain: Improvement of clinical pain in the experimental group is expected. This outcome will be assessed using the analogue, numerical categorical and McGill pain questionnaires, in the periods prior to the start of treatment, after the end of the treatment will be evaluated in the periods of 1 week, 1 month, 3 months and 6 months.;Expected outcome 2 - experimental pain: We hope to improve experimental pain in the experimental group. This outcome will be assessed through algometry, in the periods before the start of treatment, after the end of the treatment will be evaluated in the periods of 1 week, 1 month, 3 months and 6 months.

Secondary Outcome Measures

Name	Time	Method
Expected outcome 3 - quality of life: It is expected to improve the quality of life in the experimental group. This outcome will be evaluated through the SF-36 questionnaire, in the periods before the start of treatment, after the end of the treatment will be evaluated in the periods of 1 week, 1 month, 3 months and 6 months.;Expected outcome 4- manifestation of adverse events: Non-manifestation of adverse events in the experimental group is expected. This outcome will be assessed through the reports of the volunteers themselves during the treatment period.